These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 21888745)
1. Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma. Mojtahedi Z; Khademi B; Yehya A; Talebi A; Fattahi MJ; Ghaderi A J Laryngol Otol; 2012 Feb; 126(2):175-9. PubMed ID: 21888745 [TBL] [Abstract][Full Text] [Related]
2. Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Mojtahedi Z; Khademi B; Hashemi SB; Abtahi SM; Ghasemi MA; Fattahi MJ; Ghaderi A Pathol Oncol Res; 2011 Mar; 17(1):7-10. PubMed ID: 20340055 [TBL] [Abstract][Full Text] [Related]
3. NFκB-p50 as a blood based protein marker for early diagnosis and prognosis of head and neck squamous cell carcinoma. Gupta A; Kumar R; Sahu V; Agnihotri V; Singh AP; Bhasker S; Dey S Biochem Biophys Res Commun; 2015 Nov; 467(2):248-53. PubMed ID: 26435503 [TBL] [Abstract][Full Text] [Related]
4. Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Hoffmann TK; Balló H; Braunstein S; Van Lierop A ; Wagenmann M; Bier H Oral Oncol; 2001 Jan; 37(1):50-6. PubMed ID: 11120483 [TBL] [Abstract][Full Text] [Related]
5. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Bongers V; Braakhuis BJ; Snow GB Clin Otolaryngol Allied Sci; 1995 Oct; 20(5):479-82. PubMed ID: 8582085 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523 [TBL] [Abstract][Full Text] [Related]
7. Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Qiu G; Li Y; Liu Z; Wang M; Ge J; Bai X Med Oncol; 2014 Dec; 31(12):316. PubMed ID: 25373322 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of altered blood and tissue glutathione levels in head and neck squamous cell carcinoma cases. Khan SU; Mahjabeen I; Malik FA; Kayani MA Asian Pac J Cancer Prev; 2014; 15(18):7603-9. PubMed ID: 25292035 [TBL] [Abstract][Full Text] [Related]
9. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. Jebreel A; Mistry D; Loke D; Dunn G; Hough V; Oliver K; Stafford N; Greenman J J Laryngol Otol; 2007 Mar; 121(3):246-52. PubMed ID: 17040593 [TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis. Travassos DC; Fernandes D; Massucato EMS; Navarro CM; Bufalino A J Oral Pathol Med; 2018 Jan; 47(1):3-10. PubMed ID: 28600896 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma. Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866 [TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma. Goumas PD; Mastronikolis NS; Mastorakou AN; Vassilakos PJ; Nikiforidis GC ORL J Otorhinolaryngol Relat Spec; 1997; 59(2):106-14. PubMed ID: 9166881 [TBL] [Abstract][Full Text] [Related]
15. Diet and proinflammatory cytokine levels in head and neck squamous cell carcinoma. Arthur AE; Peterson KE; Shen J; Djuric Z; Taylor JM; Hebert JR; Duffy SA; Peterson LA; Bellile EL; Whitfield JR; Chepeha DB; Schipper MJ; Wolf GT; Rozek LS Cancer; 2014 Sep; 120(17):2704-12. PubMed ID: 24830761 [TBL] [Abstract][Full Text] [Related]
16. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719 [TBL] [Abstract][Full Text] [Related]
17. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract. Wang WL; Chang WL; Yeh YC; Lee CT; Chang CY; Lin JT; Sheu BS Mol Carcinog; 2013 Jun; 52(6):438-45. PubMed ID: 22241750 [TBL] [Abstract][Full Text] [Related]
18. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma. Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505 [TBL] [Abstract][Full Text] [Related]
19. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Kuropkat C; Lippert BM; Werner JA Oncology; 2002; 63(3):280-5. PubMed ID: 12381908 [TBL] [Abstract][Full Text] [Related]
20. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer. Chang PY; Kuo YB; Wu TL; Liao CT; Sun YC; Yen TC; Chan EC Clin Chem Lab Med; 2013 Jun; 51(6):1291-300. PubMed ID: 23154424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]